|  |  |  |  |
| --- | --- | --- | --- |
| **THE 9th Middle East Best of San Antonio Breast Cancer Symposium**  **10-11 January 2015** | | | |
| **DAY 1** |  |  |  |
| **TIME** | **TOPICS** | **SPEAKER** | **MODERATOR** |
| **8:30 – 8:35** | **Opening Remarks** | **Dr. Omalkhair Abulkhair** | |
| **8:35 – 10:05** | **Breast Cancer Predisposition: Gremlins and Risk Dr. Ezeldeen Ibrahim**  **Dr. Banu Arun** | | |
| **8:35 – 9:05** | **Characterizing Cancer Risks for the Carrier of Mutations BRCA1, BRCA2, PALB2 and RAD51C Genes** | **Dr. Antonis C. Antoniou** |  |
| **9:05 - 9:35** | **Risk Management of Hereditary Breast Cancer** | **Dr. Banu Arun** |  |
| **9:35 - 9:50** | **16 Year Old Long- Term Follow-up of the IBIS-I Breast Cancer Prevention Trial** | **Dr. Omalkhair Abulkhair** |  |
| **9:50-10:05** | **Coffee Break** | | |
| **10:05- 11:30** | **Hormonal Therapy Update Prof. Jean-Marc Nabholtz**  **Dr. Heba El Zawahry**  **Dr. Huda Abdulkareem** | | |
| **10:05- 10:30** | **Biomarkers for Clinical Management and Research**  **ER+** | **Dr. Susan Fuqua** |  |
| **10:30- 11:00** | **Adjuvant Endocrine Therapy in 2015 Including Soft Trail** | **Dr. Olivia Pagani** |  |
| **11:00 – 11:15** | **Fulvestrant 500mg Versus Anastrozole as First Line Treatment for Advanced Breast Cancer: Overall Survival from the Phase II ‘ First Study’** | **Dr. Ahmed Saadeddin** |  |
| **11:15- 11:30** | **The FERGI Phase II Study of the PI3K Inhibitor Pictilisib ( GDC- 0941) plus Fulvestrant plus Placebo in Patients with ER+, Aromatase Inhibitor (AI) – Resistant Advanced or Metastatic breast Cancer – Part I Results** | **Dr. Mohammed Jaloudi** |  |
| **11:30-12:40** | **Triple Negative Breast Cancer Updates Dr. Shafiqah Al Awadhi**  **Dr. Hassan Idrisi**  **Dr. Essam Murshid** | | |
| **11:30-11:45** | **The Clinical Significance of Heterogeneity in Triple Negative Breast Cancer** | **Dr. Hamdy Azim** |  |
| **11:45-12:00** | **S3-01 The TNT trial: A Randomized Phase III Trial of Carboplatin (C) Compared with Docetaxel (D) for Patients with Metastatic or Recurrent Locally Advanced Triple Negative or BRCA1/2 Breast Cancer (CRUK/07/012)** | **Dr. Sana Al Sukhun** |  |
| **12:00-12:15** | **S4-05 . Impact of Intrinsic Subtype by PAM50 and Other Gene Signatures on Pathologic Complete Response (pCR) Rates in Triple-Negative Breast Cancer (TNBC) after Neoadjuvant Chemotherapy (NACT)+/- Carboplatin (Cb) or Bevacizumab (Bev): CALGB 40603/150709 (Alliance)** | **Dr. Shaheena Dawood** |  |
| **12:15-12:40** | **Recent Management of HER2-Triple Negative Breast Cancer** | **Dr. Chris Twelves** |  |
| **12:40-1:40** | **Lunch** | | |
| **1:40-2:55** | **Update on HER2 the Breast Cancer Dr. Jamal Al Zekeri**  **Dr. Adda Bounedjar**  **Dr. Salha Bajasoum** | | |
| **1:40 – 2:10** | **HER2 Positive Breast Cancer: Insights from the Lab and Clinic** | **Dr. Taher Al Twigiri** |  |
| **2:10 -2:25** | **Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Daily Everolimus plus Weekly Trastuzumab and Paclitaxel as First-Line Therapy in Women with HER2+ Advanced Breast Cancer: BOLERO-1** | **Dr. Meteb Al Foheidi** |  |
| **2:25- 2:40** | **TBCRC023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab , with Endocrine Therapy and Without Chemotherapy, for 12 vs. 24 Weeks in Patients with HER2 Overexpressing Breast Cancer.** | **Dr. Nagi Al Saghir** |  |
| **2:40 - 2:55** | **Detrimental Effects of Sequential Compared to Concurrent Treatment of Pertuzumab plus T- DM1 in HER2+ Breast Cancer Cell Lines** | **Dr. Hassan Jaafar** |  |
| **2:55-3:30** | **Middle East Abstract** |  | **Dr. Jean-Mark Nabholtz** |
| **3:30-3:45** | **Break** | | |
| **3:45-4:30** | **Case for Discussion**   * **Dr. Omalkhair Abulkhair** * **Naghy Al Sagir** * **Dr. Amin Eltigani** | **Panelist**   * **Dr. Banu Arun** * **Prof. Jean-Mark Nabholtz** * **Dr. Mohammed AL Belwi** * **Dr. Olivia Pagani** * **Dr. Ezzelddin Ibrahim** * **Dr. Sanaa Al Sukhun** * **Dr. Hamdi Azim** * **Dr. Shafiqah Al Awadhi** | **Dr. Ahmed Saadeddin** |
| **DAY 2** |  | | |
| **8:30-10:30** | **Chemotherapy Update Dr. Sami Al Khatib**  **Dr. Mahmoud Shahin** | | |
| **8:30- 8:45** | **S2-07. A Randomized Phase III Trial Comparing Neoadjuvant Chemotherapy with Weekly Nanoparticle-Based Paclitaxel with Solvent-Based Paclitaxel Followed by Anthracyline/ Cyclophosphamide for Patients with Early Breast Cancer (GeparSepto);GBG69** | **Dr. Ahmed Al Shehri** |  |
| **8:45-9:00** | **S3-02. NSABP B-36: A Randomized Phase III Trial Comparing Six Cycle of 5-Fluorouracil (5-FU), Epirubicin, and Cyclophosphamide (FEC) to Four Cycle of Adriamycin and Cyclophoshamid (AC) in Patients (pts) with Node-Negative Breast Cancer** | **Dr. Khalid Al Saleh** |  |
| **9:00- 9:15** | **S3-03. Ten Year Update of E119:phase III Study of Doxorubicin-Cyclophosphamide Followed by Paclitaxel or Docetaxel Given Every 3 weeks or Weekly in Patients with Axillary Node-Positive or High-Risk Node-Negative Breast Cancer** | **Dr. Alaa Kandil** |  |
| **9:15- 9:30** | **S3-04. The phase III ICE study: Adjuvant Ibandronate with or without Capecitabine in Elderly Patients with Moderate or High Risk Early Breast Cancer** | **Dr. Medhat Faris** |  |
| **9:30-10:10** | **Update on Transitional Research** | **Dr. Ahmed Awada** |  |
| **10:10- 10:20** | **Coffee Break** | | |
| **10:20-11:10** | **Radiation Update Dr. Mohamed Shabana**  **Dr. Abdulrahman Al Hadab** | | |
| **10:20- 10:35** | **S5-03.Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy versus Whole Breast Irradiation : 5 –Year Survival Results of a Phase 3 Randomized Trial** | **Dr. Belal El Hawarri** |  |
| **10:35 – 11:10** | **New Insights in Beast Radiation** | **Dr. Fady Geara** |  |
| **11:10- 12:20** | **Surgical Update Dr. Osama Al Malik**  **Dr. Manal Al Zaid**  **Dr. Khalid Al Hajri** | | |
| **11:10 – 11:25** | **S5-04. A Large Prospectively-Designed Study of the DCIS Score: Predicting Recurrence Risk after Local Excision for Ductal Carcinoma in Situ Patients with and without Irradiation** | **Dr. Abdulaziz Al Saif** |  |
| **11:25-11:40** | **Posters on Sential Node** | **Dr. Dr. Mehra Golshan** |  |
| **11:40-12:00** | **Delayed and Immediate Partial Breast Reconstruction after Breast Conserving Surgery** | **Dr. Mahmoud Al Masri** |  |
| **12:00-12:20** | **Reconstruction for the High Risk Patient: Challenges of Chemotherapy, Radiation Therapy and Selection** | **Dr. Mehra Golshan** |  |
| **12:30-1:30** | **Lunch Break** | | |
| **1:30-2:00** | **Supportive Dr. Hesham El Ghazaly**  **Dr. Osama Al Hemsi** | | |
| **1:30-1:45** | **S5-07. A Randomized, Open-Label, Multicenter, Phase 3 Study of Epoetin Alfa (EPO) Plus Standard Supportive Care versus Standard Supportive Care in Anemic Patients with Metastatic Breast Cancer (MBC) Receiving Standard Chemotherapy** | **Dr. Lobna Sedky Khalil** |  |
| **1:45-2:00** | **S5-08. Final Survival Analysis from the Randomized Women’s Intervention Nutrition Study (WINS) Evaluating Dietary Intervention as Adjuvant Breast Cancer Therapy** | **Dr. Bassim Al Bahrani** |  |
| **2:00-3:00** | **Case Discussion** | **Panelists:**   * **Dr. Alaa Kandil** * **Dr. Ahmed Awada** * **Dr. Heba El Zawahry** * **Dr. Anees Hassan** * **Dr. Nour Karmani** | **Dr. Ahmed Faraj** |
| **3:00- 4:00** | **Closing Ceremony** | | |